Stephan Lücke - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Stephan Lücke's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Stephan Lücke
Verified
Editor, Bibliomed Pflege
Essen
Beats
Social Justice , Racial Equity , Cultural Identity
Features
Content
Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial
By Stephan Lücke Verified, Georg Martin Haag, Anne Katrin Berger, Ulrich Abel| Nature Verified To assess the predictive value of early metabolic response (ΔSUV) after short-term treatment with first-line cetuximab in patients (pts) with RAS-wt metastatic colorectal cancer (mCRC). In this prospective phase II study, RAS-wt mCRC pts received a single-agent cetuximab run-in therapy of 2 weeks. ΔSUV was assessed with FDG-PET/CT on days 0 and 14. Early clinical response (ECR) was evaluated with CT on day 56 after treatment with FOLFIRI-cetuximab.
By Stephan Lücke Verified| Rheinische Post Verified 1908 wurde die Dampfbahn durch eine elektrisch betriebene Straßenbahn ersetzt, die den Königlichen Hof in Moers mit dem Staatsbahnhof Homberg verband. Jahre später wurde die Strecke verlängert: Ab 1915 fuhren die Wagen von der Gastwirtschaft "Steinschen" in Hülsdonk bis zum Friedrichsplatz in Ruhrort. Zum Einsatz kamen Triebwagen eines Düsseldorfer Herstellers, die 60 Personen Platz boten. Sie waren in einem hellen Gelbton angestrichen und mit Goldlinien verziert.
Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial
By Stephan Lücke Verified, Georg Martin Haag, Anne Katrin Berger, Ulrich Abel| Nature Verified To assess the predictive value of early metabolic response (ΔSUV) after short-term treatment with first-line cetuximab in patients (pts) with RAS-wt metastatic colorectal cancer (mCRC). In this prospective phase II study, RAS-wt mCRC pts received a single-agent cetuximab run-in therapy of 2 weeks. ΔSUV was assessed with FDG-PET/CT on days 0 and 14. Early clinical response (ECR) was evaluated with CT on day 56 after treatment with FOLFIRI-cetuximab.
Company Info
Bibliomed Pflege